AKSO HEALTH GROUP (AHG) Fundamental Analysis & Valuation
NASDAQ:AHG • US98422P1084
Current stock price
2.35 USD
-0.01 (-0.42%)
At close:
2.37 USD
+0.02 (+0.85%)
Pre-Market:
This AHG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AHG Profitability Analysis
1.1 Basic Checks
- In the past year AHG has reported negative net income.
- AHG had a positive operating cash flow in the past year.
- AHG had negative earnings in each of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: AHG reported negative operating cash flow in multiple years.
1.2 Ratios
- AHG has a Return On Assets of -62.79%. This is amonst the worse of the industry: AHG underperforms 88.00% of its industry peers.
- AHG has a worse Return On Equity (-67.79%) than 72.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.79% | ||
| ROE | -67.79% | ||
| ROIC | N/A |
ROA(3y)-25.43%
ROA(5y)-42.59%
ROE(3y)-30.24%
ROE(5y)-85.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- AHG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. AHG Health Analysis
2.1 Basic Checks
- AHG does not have a ROIC to compare to the WACC, probably because it is not profitable.
- AHG has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 48.64 indicates that AHG is not in any danger for bankruptcy at the moment.
- AHG's Altman-Z score of 48.64 is amongst the best of the industry. AHG outperforms 100.00% of its industry peers.
- The Debt to FCF ratio of AHG is 1.96, which is an excellent value as it means it would take AHG, only 1.96 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of AHG (1.96) is better than 77.00% of its industry peers.
- AHG has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.01, AHG belongs to the top of the industry, outperforming 85.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.96 | ||
| Altman-Z | 48.64 |
ROIC/WACCN/A
WACC7.53%
2.3 Liquidity
- A Current Ratio of 14.20 indicates that AHG has no problem at all paying its short term obligations.
- AHG has a Current ratio of 14.20. This is amongst the best in the industry. AHG outperforms 99.00% of its industry peers.
- AHG has a Quick Ratio of 14.18. This indicates that AHG is financially healthy and has no problem in meeting its short term obligations.
- AHG has a Quick ratio of 14.18. This is amongst the best in the industry. AHG outperforms 99.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.2 | ||
| Quick Ratio | 14.18 |
3. AHG Growth Analysis
3.1 Past
- AHG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -146.56%.
- The Revenue has grown by 512.09% in the past year. This is a very strong growth!
- AHG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.45% yearly.
EPS 1Y (TTM)-146.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-374.64%
Revenue 1Y (TTM)512.09%
Revenue growth 3Y35.05%
Revenue growth 5Y16.45%
Sales Q2Q%415.75%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. AHG Valuation Analysis
4.1 Price/Earnings Ratio
- AHG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- AHG's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. AHG is more expensive than 66.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1261.98 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. AHG Dividend Analysis
5.1 Amount
- AHG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AHG Fundamentals: All Metrics, Ratios and Statistics
2.35
-0.01 (-0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)12-04 2023-12-04
Earnings (Next)N/A N/A
Inst Owners0.02%
Inst Owner Change10.8%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.29B
Revenue(TTM)14.78M
Net Income(TTM)-134.98M
AnalystsN/A
Price TargetN/A
Short Float %0.03%
Short Ratio0.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 87.34 | ||
| P/FCF | 1261.98 | ||
| P/OCF | 1096.35 | ||
| P/B | 6.48 | ||
| P/tB | 7.15 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.29
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY0.08%
OCF(TTM)0
OCFY0.09%
SpS0.03
BVpS0.36
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.79% | ||
| ROE | -67.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 6.92% |
ROA(3y)-25.43%
ROA(5y)-42.59%
ROE(3y)-30.24%
ROE(5y)-85.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.96 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.19% | ||
| Cap/Sales | 1.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 14.2 | ||
| Quick Ratio | 14.18 | ||
| Altman-Z | 48.64 |
F-Score4
WACC7.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-146.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-374.64%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)512.09%
Revenue growth 3Y35.05%
Revenue growth 5Y16.45%
Sales Q2Q%415.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.88%
OCF growth 3YN/A
OCF growth 5YN/A
AKSO HEALTH GROUP / AHG Fundamental Analysis FAQ
What is the fundamental rating for AHG stock?
ChartMill assigns a fundamental rating of 3 / 10 to AHG.
Can you provide the valuation status for AKSO HEALTH GROUP?
ChartMill assigns a valuation rating of 0 / 10 to AKSO HEALTH GROUP (AHG). This can be considered as Overvalued.
Can you provide the profitability details for AKSO HEALTH GROUP?
AKSO HEALTH GROUP (AHG) has a profitability rating of 1 / 10.